1	Title: A text messaging intervention to support patients with chronic pain during prescription
2	opioid tapering: protocol for a double-blind randomised controlled trial
3	
4	Running Title: Text messaging support for chronic pain
5	
6	Word Count: 4517 (main manuscript only, excluding title page, abstract, references, figures,
7	tables, acknowledgments).
8	
9	Authors and Affiliations
10	Ali Gholamrezaei ¹ , MD, PhD; Email: ali.gholamrezaei@sydney.edu.au
11	Michael R Magee ¹ , MA; Email: mmag9080@uni.sydney.edu.au
12	Amy G McNeilage ¹ , BA; Email: amy.mcneilage@sydney.edu.au
13	Leah Dwyer ² , BA; Email: kleahwesley@gmail.com
14	Hassan Jafari ³ , MSc, PhD; Email: hassan.jafari@kcl.ac.uk
15	Alison Sim ¹ , MA; Email: alisonsim213@gmail.com
16	Manuela L Ferreira ⁴ , BPTh, MSc, PhD; Email: manuela.ferreira@sydney.edu.au
17	Beth D Darnall ⁵ , PhD; Email: bdarnall@stanford.edu
18	Paul Glare ¹ , MBBS, FRACP, MM; Email: paul.glare@sydney.edu.au
19	Claire E Ashton-James ¹ , PhD Email: claire.ashton-james@sydney.edu.au
20	
21	¹ Pain Management Research Institute, Kolling Institute, The University of Sydney, St
22	Leonards NSW, Australia
23	² Consumer Advisory Group, Painaustralia, Deakin ACT, Australia
24	³ Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and
25	Neuroscience, King's College London, United Kingdom

- ⁴ Sydney Musculoskeletal Health, Kolling Institute, Faculty of Medicine and Health, The
- 2 University of Sydney, St Leonards NSW, Australia
- ⁵ Department of Anaesthesiology, Perioperative and Pain Medicine, Stanford University
- 4 School of Medicine, Stanford, CA, United States
- 5

6 Correspondence Author

- 7 A/Prof. Claire E Ashton-James.
- 8 Postal address: Pain Management Research Centre, Ground Floor Douglas Building, Royal
- 9 North Shore Hospital, St Leonards, NSW, Australia, 2065.
- 10 Email: claire.ashton-james@sydney.edu.au
- 11
- ____
- 12
- 13
- 14
- 15
- 16

1 Abstract

Introduction Increases in pain and interference with quality of life is a common concern among people with chronic non-cancer pain (CNCP) who are tapering opioid medications. Research indicates that access to social and psychological support for pain self-management may help people to reduce their opioid dose without increasing pain and interference. This study evaluates the efficacy of a text messaging intervention designed to provide people with CNCP with social and psychological support for pain self-management while tapering longterm opioid therapy (LTOT) under the guidance of their prescriber.

9 Methods and analysis A double-blind randomised controlled trial will be conducted. 10 Patients with CNCP (n = 220) who are tapering LTOT will be enrolled from across Australia. Participants will continue with their usual care while tapering LTOT under the supervision of 11 12 their prescribing physician. They will randomly receive either a psycho-educational video 13 and supportive text messaging (two SMS per day) for 12 weeks or the video only. The 14 primary outcome is the pain intensity and interference assessed by the Pain, Enjoyment of 15 Life and General Activity scale. Secondary outcomes include mood, self-efficacy, pain cognitions, opioid dose reduction, withdrawal symptoms, and acceptability, feasibility, and 16 17 safety of the intervention. Participants will complete questionnaires at baseline and then 18 every four weeks for 12 weeks and will be interviewed at week 12. This trial will provide 19 evidence for the efficacy of a text messaging intervention to support patients with CNCP who 20 are tapering LTOT. If proven to be efficacious and safe, this low-cost intervention can be 21 implemented at scale.

Ethics and dissemination The study protocol was reviewed and approved by the Northern
Sydney Local Health District (Australia). Study results will be published in peer-reviewed
journals and presented at scientific and professional meetings.

1	Trial	registration number ACTRN12622001423707.
2		
3	KEYV	WORDS: Opioid, pain, tapering, digital health, mHealth, mobile health
4		
5	Streng	gths and limitations of this study
6	1.	This protocol describes a double-blind randomised controlled trial in which patients,
7		clinicians, investigators, outcome assessors, and statistician will all be blind to group
8		allocation.
9	2.	The intervention was co-designed with input from both patients and clinicians and
10		further refined based on feedback received during a pilot study of the intervention.
11	3.	The design and procedures of this trial were informed by the feasibility and potential
12		efficacy measures of a pilot trial.
13	4.	By using a broad community-based sample, this study aims to conduct more inclusive
14		pain research and investigate the barriers and facilitators of implementing digital
15		support on a larger scale.
16	5.	Designing a sham or placebo control that is completely identical to the intervention is
17		a challenge for a digital intervention. The active control may provide benefits to its
18		recipients, potentially leading to an underestimation of the actual effect size of the
19		digital support.
20		

1 Introduction

2 Background and rationale

Chronic pain conditions are among the leading causes of disability worldwide.¹ Whilst opioid medications are commonly prescribed for the management of chronic non-cancer pain (CNCP),² prescribing guidelines have changed recently due to evidence of limited benefits and dose-related harms associated with long-term opioid therapy (LTOT).³ Consequently, patients with CNCP are increasingly being advised to gradually reduce the dose or discontinue LTOT (i.e., tapering) under clinical supervision.⁴

9 Systematic reviews suggest that, on average and over the long term, tapering opioids for patients with CNCP is not associated with increased pain and can be associated with 10 improved functioning and quality of life.⁵⁶ However, patients' experiences of opioid tapering 11 vary widely.⁷ Opioid dose reduction can lead to unpleasant withdrawal symptoms and 12 negatively impact mood and pain.^{7 8} Recent retrospective studies have also raised concerns 13 about the risk of overdose and serious harm associated with opioid tapering.⁹ Several studies 14 indicate that the trajectory of patients' experiences during tapering LTOT may depend on 15 their access to various forms of support, including pain education, routine monitoring, a 16 strong patient-provider relationship, and strategies for managing pain and withdrawal 17 symptoms.⁵⁷¹⁰¹¹ However, access to these forms of support is often a pervasive challenge.⁸¹² 18 13 19

Digital health technologies using mobile phones (mobile health or mHealth) are emerging as a solution to the global challenge of providing patients with access to support for health behaviour change.^{14 15} They can be a cost-effective way to deliver healthcare services on a large scale, particularly when they are used to address chronic conditions, and can be readily adapted to the needs of diverse demographic groups and health conditions.^{14 16 17} A recent systematic review found that digital health interventions can help to improve pain

6

interference and severity, psychological distress, and health-related quality of life in people
 with chronic pain.¹⁸ However, evidence for the effectiveness of digital health interventions to
 support patients with CNCP during tapering LTOT is limited but promising.¹⁹

Our previous research has shown that people with CNCP have generally positive attitudes 4 towards using digital health technologies, particularly mobile text messaging (SMS), to 5 support them with opioid tapering.²⁰ Studies have also shown that educational videos may be 6 7 an effective means of providing patients with information about chronic pain, pain selfmanagement, and opioid tapering,²¹⁻²³ and can increase the opioid-tapering self-efficacy of 8 people currently on LTOT for chronic pain.²¹ Based on this foundational research, we co-9 designed a digital intervention (video and mobile text messaging) for patients with CNCP 10 who are tapering prescription opioids under clinical supervision.²⁴ Patients and clinicians 11 12 have rated this program as appropriate, useful, and likely to be effective in supporting patients during opioid tapering.²⁴ A pilot randomised controlled trial (RCT) has been 13 conducted, demonstrating the feasibility, acceptability, and potential efficacy of this 14 intervention in patients referring to public and private outpatient pain management clinics.²⁵ 15 26 16

17 Therefore, in this study, we aim to evaluate the efficacy (primary objective) of our text messaging intervention to improve patients' outcomes in a larger and more diverse 18 population in Australia. To conduct more inclusive pain research,²⁷ this study will use a broad 19 community sample rather than merely recruiting through specialist pain clinics which are not 20 easily accessible to most patients.²⁸ Using a community sample will also enable us to 21 22 investigate the barriers and facilitators of implementing this digital support on a large scale 23 and to prepare strategies accordingly. Since, compared to our pilot RCT, the study setting and 24 population have changed in this RCT and some aspects of the intervention have been 25 modified (e.g., duration and content), we will re-evaluate the feasibility, acceptability, and

7

safety of the intervention (secondary objectives). If found to be feasible, acceptable, safe, and
 efficacious, this digital health support can be evaluated in future cost effectiveness/implementation trials as a solution to improve outcomes and reduce the harms
 of LTOT in patients with CNCP.

5 **Objectives**

6 The primary objective of this RCT is to evaluate the efficacy of a text messaging intervention in reducing pain intensity and interference (as measured by the Pain, Enjoyment of Life and 7 General Activity (PEG) scale)²⁹ in patients with CNCP during tapering LTOT. Secondary 8 9 objectives are A) to evaluate the efficacy of the intervention in reducing the severity of anxiety and depression symptoms, increasing opioid tapering self-efficacy and pain self-10 11 efficacy, reducing pain catastrophising, reducing the opioid dose, and reducing withdrawal 12 symptoms, B) to evaluate the feasibility, acceptability, and safety of the intervention, C) to 13 explore mechanisms of action and predictors of response to the intervention, and D) to identify barriers and facilitators of future implementation of the intervention at large-scale. 14

15

16 Methods and analysis

This report is prepared according to the Standard Protocol Items: Recommendations forInterventional Trials (SPIRIT, see Appendix 1 for the SPIRIT checklist).

19 Patient and public involvement

The development of this mHealth intervention was in response to previous research conducted by our team, as well as others, on patients' experiences and needs during tapering opioid medications,^{7 8 12} and their perspectives on receiving support via mHealth interventions.²⁰ As described previously, the mHealth intervention prototype was developed in close collaboration with clinician-researchers and a consumer representative.²⁴ It was revised in response to feedback from panels of consumers and clinical experts, and then was

8

tested in a pilot study.²⁵ The intervention content and delivery were further improved based 1 on the feedback received from those who participated in the pilot study.²⁶ Similarly, the 2 design (procedures and measures) of the pilot trial²⁵ as well as the current, more definitive 3 trial was developed in close collaboration with clinician-researchers and a consumer 4 representative. Moreover, feasibility data and feedback received from those who participated 5 in the pilot study were considered in designing this trial.²⁶ 6

Study design 7

This is a double-blind RCT with two parallel arms (Figure 1) to test the primary hypothesis 8 9 which is the superiority of receiving an educational video followed by daily text messages 10 (SMS) compared with receiving an educational video alone, both in addition to usual care, in 11 reducing pain intensity/interference.

12

[To place *Figure 1 Study flow diagram* approximately here]

13 There is currently no gold-standard 'placebo' control for digital health interventions and 14 designing a sham condition for such interventions is challenging. Using an active control 15 condition (i.e., educational video) together with 'limited disclosure' in the current study (see Blinding/Masking) will allow us to achieve blinding (masking) while complying with the 16 national standards on ethical conduct in human research.³⁰ 17

18 Study setting

19 Participants will be recruited from across Australia. Flyers (Appendix 2) will be used to identify potential participants via social media, newspapers, public notice boards, community 20 21 events, websites, and email lists.

22 Participants, screening, and recruitment procedures

23 The study flyers contain a link to the study webpage (Appendix 2) which provides brief 24 information about the study and access to the Participant Information Sheet (PIS, Appendix

- 1 3) and an online self-report screening form (Appendix 4) to check eligibility (Table 1). Those
- 2 who are eligible will be requested to consent online (Appendix 3).
- 3

Table 1: Eligibility criteria ^a

Inclusion criteria

- A resident of Australia,
- Age 18 years or older,
- Having a chronic (\geq 3 months) non-cancer pain condition,³¹
- Using opioid analgesics for at least four weeks before enrolment,^{3 b}
- Has started or is starting to reduce opioid dose under the supervision of a physician (e.g.,

General Practitioner),

- Willing to provide contact details of their physician,
- Able to understand written and spoken English well,
- Owns a mobile phone that can receive text messages,
- Has access to the internet via their mobile phone (Data or Wi-Fi),
- Able to give written informed consent and comply with the study procedures.

Exclusion criteria

- Having opioid or other substance use disorder,
- Having a poorly controlled or unstable mental illness,
- Suicidal ideation or attempt in the past 12 months,
- Major surgery in the past 6 months or scheduled in the next 3 months such as surgery to

the organs of the head, chest, and abdomen,

- Participation in another clinical trial concurrently,
- Pregnancy.

^a Eligibility is checked using an online self-administered screening form (Appendix 4)

10

^b The National Real Time Prescription Monitoring system³² will be used for verification

1

2

3 Interventions

4 Usual care

5 In this study, usual care is defined as any care that each participant receives at the discretion 6 of their prescriber (e.g., their General Practitioner), which may or may not include 7 multidisciplinary care. Participants in the current study are those who are tapering their opioid medications under the supervision of their prescribing physician. This physician is 8 9 responsible for the monitoring and management of withdrawal symptoms and other possible 10 adverse events during opioid tapering. Importantly, participation in this clinical trial does not 11 involve clinical decisions around reducing opioids, the rate of dose reduction, or any other 12 care that participants may be receiving. Participation in this study lasts for a total duration of 13 12 weeks.

14 Intervention group

15 After signing the consent form and completing baseline questionnaires, participants will be 16 randomised (1:1) into two groups (Figure 1). Participants in the intervention group will 17 receive a welcoming message and a message with a link to a psycho-educational video to 18 watch (day 1) followed by daily text messages on their mobile phones for 12 weeks. The 19 video and library of the messages were developed based on a co-design study, driven by the 20 Social Cognitive Theory (with emphasis on the self-efficacy construct) and direct feedback from consumers and clinicians.²⁴ The contents have been revised further based on feedback 21 received during a pilot RCT.²⁵ The psycho-educational video is composed of narrated, 22 23 animated PowerPoint slides with a duration of 11 minutes providing information about pain, 24 opioid tapering, and pain self-management strategies as well as socioemotional support in the

11

form of testimonials. The content of the text messages serves to reinforce and remind people about the content of the psycho-educational video as well as messages of support and reassurance (see examples in Table 2 and Appendix 5).²⁵ Starting from day 2, participants will receive daily text messages (2 SMS/day, 7 days/week) for 12 weeks (135 unique messages, 20% repeated messages, and 5 messages for assessment notifications). The text messaging duration for this study is based on patients' feedback in the pilot study.²⁵

7

Table 2: Examples of SMS text messages

Pain management information

"Pain flare ups are like bad moods. Sometimes they come on for no clear reason. They will often pass if you distract yourself. Try doing or thinking about something you enjoy." "Slow, deep breathing can help manage stress and pain. Breathe in deeply for about 4 counts - feel your stomach expand. Hold that breath for 2 counts and then breath out slowly for 4 counts. Notice the relaxation spread through your body. Try this for a few minutes."

Opioid tapering information

"Opioid medication becomes less effective over time. It might be surprising but after a gradual reduction many people say their pain is more manageable and less distressing." "Hi [first name], sometimes it takes our body time to adjust to changes in medication. Withdrawal symptoms while reducing your opioid medication are temporary and will pass."

Socioemotional support/reassurance

"It's normal to feel irritable or low while reducing opioids. It's a big change and your body needs time to adjust. Try to be kind to yourself."

"[first name], you are doing your best in a challenging situation. Be proud of yourself."

12

1

Message delivery will be managed by Twilio (Twilio Inc, San Francisco, California) and will be one-way (i.e., recipients cannot reply directly to messages). Messages will be sent over Australian telephone networks at no cost to individual participants. Messages will be sent at ~10 AM and ~4 PM (local time). The messages sent to the participants are standardised in their content and delivery (by day of study and by the time of day; AM/PM). Participants' first names are used in a selection of messages to increase engagement (e.g., "Hi John...").

9 Before watching the educational video and receiving the first daily text messages, 10 participants in the intervention group will receive an information sheet (Appendix 6) 11 outlining the digital support they will receive (i.e., the educational video and daily text 12 messages). Participants will be informed that the text messages are one-way. They can cease 13 receiving text messages by emailing or calling the research team. Participants will be asked 14 whether they are willing to receive daily text messages (i.e., the second consent step). If they 15 do not agree to receive daily text messages, they can continue with just watching the 16 educational video (see *Statistical Methods* for sensitivity analysis).

17 *Control group*

Participants in the control group similarly will receive a link to an educational video (i.e., active control) to watch after randomisation (day 1) but will not receive daily text messages. The content of the video is identical to the video in the intervention group except that it does not include information/testimonials about receiving daily text messages and the duration is lo minutes (see *Blinding Arrangements*). Before watching the educational video, participants in the control group will also receive an information sheet (Appendix 6) outlining the digital support they will receive (i.e., the educational video).

25 **Outcomes**

1	The study primary and secondary outcomes are selected based on the recommendations of the
2	Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) ^{33 34}
3	To minimise participant burden, we will use short-form versions of previously validated
4	questionnaires as described below and at the times specified in Table 3.
5	

	Description	Baseline	Week 4	Week 8	Week 12
Demographics –	Age, Gender, Socioeconomic,				
Clinical data	Pain, Medications, Current care,	X			
	Tapering history				
Decision	Single-item CPSPost	X			
Social support	OSSS-3	X			
Pain	3-item PEG scale	X	Х	Х	X
Opioid dose, OME	Self-report, prescription history	X	Х	X	Х
Emotional functioning	PHQ-2 and GAD-2	X	Х	X	Х
Self-efficacy in tapering	Single-item OTSEQ ^a	X	X	X	X
Pain cognitions	CAP-6 and PSEQ-2	X	X	X	X
Withdrawal symptoms	Open-ended question		X	Х	X
Current care	Self-report visits for pain	X	X	X	X
Global improvement	PGIC scale				X
Adverse events	NEQ				X
Acceptability	Feedback survey, interview				X

14

Feasibility	Recruitment, dropout, delivery	X
Abbreviations: PEG: Pai	n Enjoyment of life General activity s	cale; PGIC: Patient Global
Impression of Change;	CPSPost: Control Preferences Scale	e; PHQ-2: Patient Health
Questionnaire-2; GAD-	2: Generalized Anxiety Disorder-2;	; OME: Oral Morphine
Equivalents; CAP-6:	Concerns about Pain Scale; PSE	Q-2: Pain Self-Efficacy
Questionnaire; OSSS-3:	Oslo Social Support Scale. ^a OTSE	EQ will be repeated after
watching the video.		

1

2 *Primary outcome*

The primary outcome in this study is the PEG scale score at 12 weeks after enrolment.²⁹ The 3 3-item PEG scale is a subset of the Brief Pain Inventory scale³⁵ and has an 11-point NRS for 4 each of the three domains of pain intensity, pain interference with general activity (physical 5 interference), and pain interference with enjoyment of life (affective interference).³⁶ Ratings 6 are from 0 ('no pain'/'does not interfere') to 10 ('pain as bad as you can 7 8 imagine'/'completely interferes'). The total score is the average of the 3 items (ranging from 9 0 to 10). The minimal clinically important difference (MCID) in the PEG scale has been 10 evaluated in several studies and is reported from 1 to 2.5 points (out of 10). We will consider at least 1 point difference between the two groups in the PEG scale to be a clinically 11 important difference in this study.^{29 37 38} 12

13 Secondary outcome measures

• Emotional functioning 12 weeks after enrolment: We will measure the severity of *anxiety* and *depression* symptoms with the Generalised Anxiety Disorder-2 (GAD-2)³⁹ and the Patient Health Questionnaire-2 (PHQ-2),⁴⁰ respectively. Each questionnaire contains 2 items on anxiety/depression symptoms and the responses range from 0 ('Not at all') to 3 ('Nearly every day'). Total score is the sum of the scores for each questionnaire and ranges from 0 to

15

A cut-point score of 3 or greater in each scale is generally used for screening
 depression/anxiety.^{39 40}

Participant's rating of global improvement 12 weeks after enrolment: We will measure
global improvement using the Patient Global Impression of Change (PGIC) scale, a 7-point
Likert scale with ratings ranging from 'Very much improved' to 'Very much worse'.⁴¹

Cumulative incidence of withdrawal symptoms 12 weeks after enrolment: We will
evaluate the experience of withdrawal-like symptoms every 4 weeks during the study period
using a binary question (Yes/No) followed by an open-ended prompt for patients to explain
the experienced symptoms.⁴²

• Percentage of opioid dose reduction 12 weeks after enrolment: To measure opioid dose 10 reduction, we will use two sources of information: 1) participants' self-reports of their current 11 12 medication (i.e., drug names, doses, regimen) at baseline and then every 4 weeks; 2) 13 prescription history obtained from The National Real Time Prescription Monitoring system (RTPM). The RTPM is a nationally implemented system in Australia that collects prescribing 14 15 and dispensing information about monitored medicines via electronic prescription exchange 16 services. The National Data Exchange component of the RTPM captures information from 17 state and territory regulatory systems, prescribing and dispensing software, and a range of external data sources.³² The total daily dose (TDD) of opioids will be converted to mg of oral 18 19 morphine equivalents (OME) and the percentage of reduction from baseline will be calculated.43 20

Self-efficacy 12 weeks after enrolment: We will measure pain self-efficacy using the 2item Pain Self-Efficacy Questionnaire (PSEQ-2) which assesses confidence in the ability to
do tasks and activities despite pain with ratings ranging from 0 ('not at all confident') to 6
('completely confident') and the total sum score ranging from 0 to 12.⁴⁴ In addition, we will
measure self-efficacy in reducing opioid medications using the Opioid Tapering Self-Efficacy

16

1 Questionnaire (OTSEQ) which we developed based on Bandura's self-efficacy theory.⁴⁵ The 2 OTSEQ measures self-efficacy to taper prescription opioids in the presence of chronic pain 3 using one item (general self-efficacy). Participants rate their confidence by selecting a 4 number from 0 ('not at all confident') to 100 ('completely confident'). The face validity of 5 the questionnaire has been evaluated by a panel of clinicians during the co-design process and 6 cognitive debriefing was conducted by interviewing six patients with CNCP who had 7 experienced opioid tapering.

Concerns about pain 12 weeks after enrolment: Pain catastrophising cognitions will be
measured using the 2-item Concerns About Pain scale (CAP-6).⁴⁶ Ratings range from 1
('never') to 5 ('always') and the total sum score ranges from 6 to 30.

• Acceptability of digital support will be measured using a survey at the end of the study period. The survey design was based on previous studies,⁴⁷ including our pilot RCT,²⁵ and contains Likert scales and open-ended questions about the usefulness, readability, and acceptability of the digital support. We will also conduct a semi-structured interview at the end of the study period in both groups to gain a deeper understanding of participants' experiences and views of the content and delivery of the digital support.

• Feasibility of digital support will be evaluated at the end of the study according to the *number* of messages delivered/not delivered which will be recorded automatically by the text message system. Moreover, *participant disposition* will be reported according to the IMMPACT recommendation³³ including the recruitment process, adherence, and study completion data, the use of concomitant care (e.g., healthcare visits), and any protocol deviations. This information will be extracted from the data collection software (Research Electronic Data Capture, REDCap).⁴⁸

• Potentially adverse and unwanted events 12 weeks after enrolment: Participants will complete the 20-item Negative Effects Questionnaire at the end of the study. This is a tool

17

commonly used to examine potential adverse and unwanted events in psychological
 treatments.⁴⁹

3 *Other study measures:*

4 Demographic (age, gender), socioeconomic (education, employment, marital status, language and English proficiency, state, place of usual residence), and clinical data (pain condition and 5 6 duration, current care, tapering history) will be collected at the beginning of the study using a self-administered questionnaire. To further explore the factors that may be associated with 7 8 treatment response, patient involvement in the decision to taper opioids will be measured 9 using the single-item Control Preferences Scale (CPS_{Post} version) which evaluates *perceived* role position after consultation with ratings from 1 ('I made my decision alone') to 5 ('My 10 doctor made the decision').⁵⁰ The Oslo Social Support Scale (OSSS-3) will be used for 11 measuring perceived social support.⁵¹ 12

13 Assignment of interventions

14 *Allocation*

We will use the REDCap system for managing enrolment, randomisation, and data 15 collection.⁴⁸ Participants will be enrolled in the study by a Research Assistant (RA). After 16 17 completing the baseline questionnaires, the RA will use REDCap to randomly allocate the 18 participant to a study group based on the randomisation table embedded in REDCap. The 19 randomisation table will be generated at the beginning of the study by an independent 20 member of our Clinical Trial Unit using Research Randomizer (https://www.randomizer.org/). Access to this table in REDCap will be limited for the 21 22 research team members. The RA can only see the assigned group after (but not before) the 23 allocation (concealed allocation) as this is required for managing the delivery of 24 interventional text messages via the text message system.

25 Blinding/Masking

18

1 Participants, their clinicians, data collectors, research team members (except the RA who 2 manages the text messaging system), and statisticians are all blinded to the group allocation. Participants will be informed by the PIS (Appendix 3) that they will be randomly allocated 3 into two groups and that both groups will receive 'digital health support'. They will be 4 informed that the study's aim is to evaluate whether digital health support can improve health 5 6 outcomes in patients with chronic pain during reducing opioid medications. This limited disclosure of the study aim is required to maintain blinding (masking) but does not involve 7 deception.³⁰ This method is recommended for "Improving Blinding Integrity and Reporting 8 in Psychotherapy Trials".⁵² After randomisation and before receiving the digital support, 9 participants in both groups will become aware of the details of the digital support that they 10 will receive but will not become aware of the other group (Appendix 6). Participants will be 11 12 asked not to discuss the details of the digital health support they receive with the clinician supervising their opioid tapering for the duration of the study.⁵² The study RA will not be 13 14 blinded to the group allocation but will not be involved in data collection after randomisation. 15 Questionnaires will be completed online (self-administered). For other data (e.g., feasibility 16 data) groups are not known to the data collectors.

17 Data collection and management

18 Participants will complete questionnaires developed in REDCap and delivered online at the 19 time points specified in Table 3. The link to the REDCap surveys will be sent to the participant's email address and text messages will be sent to their mobile phone as a 20 notification and, if needed, as a reminder to complete the surveys.⁵³ Semi-structured 21 22 interviews will be conducted over the phone at the end of the study (week 12). The interviews 23 will be audio-recorded and transcribed. Participants will be invited for interview, 24 consecutively as they finish the study until a diverse range of in-depth experiences are captured.⁵⁴ Feasibility data including the number of messages delivered will be extracted 25

19

from the SMS software. Data including enrolment, refusals, drop-outs, and withdrawal from
 the study will be extracted from REDCap records.

3 Statistical methods

4 Sample size

5 With a 2-sided α level of 0.05, a study power of 0.8, a standard deviation (SD) of 2.5 points

6 in the PEG scale score (primary outcome measure), and assuming a 10% drop-out rate, we

7 require 220 participants in total to detect 1 point difference (MCID of PEG, Cohen's d = 0.4)

8 between the two study groups in mean PEG score after 12 weeks.

9 *Statistical analysis*

10 Researchers conducting analyses will be blinded to the group status. Our primary outcome is 11 the PEG scale total score at 12 weeks post-randomisation. The study primary hypothesis (H1) 12 is that the PEG scale total score at 12 weeks after randomisation is lower in the intervention 13 compared to the control group. To test this hypothesis, a linear mixed model containing fixed 14 effects of treatment group, time, and time x group interaction as well as baseline values of the 15 outcome, will be used. A planned contrast (i.e., the between-group difference at week 12) will be used to test the study primary hypothesis. We will also include the measures of the 16 17 PEG scale at 4 and 8 weeks after randomisation in our primary analysis model, so that in the 18 case of missingness at 12 weeks, the model can use these data to obtain a better estimate despite the missingness by applying maximum likelihood methods (i.e., including the random 19 20 effect of participants and fixed effect of time). This approach provides valid inferences under 21 the assumption that the mechanism of missing data is ignorable (or Missing At Random). To 22 account for the correlation between repeated measures at 4, 8, and 12 weeks, a random 23 intercept will be included at the subject level. We will explore if the baseline adjusted model 24 (i.e., including baseline values of the dependent variable in the model as a covariate) can 25 improve the precision of the estimates based on the fit statistics and residual distribution.

20

Normal distribution of the residuals will be tested. If departing from normality, first we will
 look for a more appropriate distribution shape and data will be transformed if appropriate to
 approximate residuals to normality.

4 Similarly, a linear mixed model will be used to analyse the study secondary outcomes with repeated measures after randomisation (e.g., emotional functioning). To analyse 5 6 continuous clinical secondary outcomes, we will use the same model as the primary analysis. 7 This involves linear mixed models that incorporate outcome measures at all available time 8 points, along with a group x time interaction term that enables estimation of the difference 9 between arms at each time point. For binary secondary outcomes, we will employ a logistic 10 mixed effects model, again including the outcome at all available time points and with two levels. The statistical significance will be defined as P < 0.05 (two-sided) and the effect 11 12 estimates will be reported with corresponding Confidence Intervals (CIs). Cohen's d (effect 13 size) will be calculated based on the estimates and standard errors. Analyses will be 14 conducted using SAS software (v 9.4, SAS Institute Inc., Cary, NC, USA).

15 *Explorative analysis*

16 The PEG scale total score is the primary outcome measure to test the efficacy of the 17 intervention according to the pre-specified MCID for this measure. However, each of the 18 PEG scale items will also be analysed and reported separately with explorative aims. 19 Explorative analyses will be done to investigate trends of change in outcomes within- and 20 between-group (i.e., group x time interaction effect) and potential moderating and mediating factors.⁵⁵ Model statement and parameters (i.e., estimation method, covariance structure) will 21 22 be determined based on the fit statistics and residuals' distribution. In addition to marginal 23 linear mixed models (where time is a categorical variable), linear mixed models (where time 24 is a continuous variable) with random intercept and random slope will also be conducted. 25 Pairwise contrasts will be done to compare the outcomes between the two groups at weeks 4

21

1 and 8. In these explorative analyses, *P* value adjustment will be done to account for multiple

- 2 comparisons according to the Holm–Bonferroni method.⁵⁶
- 3 Sensitivity analyses and missing data imputation

Sensitivity analyses will be done with both per-protocol and intention-to-treat (ITT) analyses based on drop-outs and missing data, as well as based on participants' compliance (e.g., refusing to receive SMS if allocated to).⁵⁷ For the analyses where all levels of the repeated measures are included in the model as the dependent variable, missing data will be imputed by the mixed-model analysis without any further ad hoc imputation unless when only a baseline value is available.⁵⁸ In such a case, selective imputation will be done using the baseline observation carried forward method.⁵⁷

11 *Qualitative analysis*

For feasibility and acceptability outcomes, a mixed-method analysis will be conducted on quantitative-qualitative data. Transcripts and digital notes will be entered into NVivo (version 12, QSR International). Thematic analysis using an inductive approach will be followed. The 15 Consolidated Framework for Implementation Research will be used to organise 16 implementation barriers and facilitators into major constructs.⁵⁹

- 17 Ethics and dissemination
- 18 *Research ethics approval and protocol*

This study has approval from the Northern Sydney Local Health District Research Ethics and
Governance (2022/ETH01795, 2022/STE02938). The initially approved protocol version was
1.02 (dated 11 October 2022). The protocol has been revised before enrolment (version 1.3
dated 19 January 2023). The trial was prospectively registered at the Australian New Zealand
Clinical Trials Registry (ACTRN: ACTRN12622001423707).

24 Dissemination

22

Study results will be published in peer-reviewed journals and presented at scientific and
 professional meetings.

3

4 **Discussion**

5 This study describes the protocol for a double-blind RCT to test the efficacy of a co-designed 6 digital health intervention to support people with CNCP during tapering LTOT. Other 7 outcomes include feasibility, acceptability, and safety of the intervention. The intervention 8 content and the trial protocol have been co-designed in collaboration with patients with 9 chronic pain and clinicians specialising in pain management. If proven to be efficacious, this 10 digital support can be a low-cost intervention to be implemented at a large scale.

There are limitations in the design of this trial that should be acknowledged. We 11 12 acknowledge that there may be substantial variation in opioid dose changes attempted by 13 participants over the 12-week study period, and there is likely to be significant variation in 14 participants' satisfaction, engagement with, and adherence to the 'usual care'. However, 15 heterogeneity in participants' opioid tapering schedules and usual care will allow us to capture potential feasibility challenges. Moreover, it would be impractical and potentially not 16 beneficial to the principle of patient-centred care to standardise 'usual care' or standardise 17 opioid tapering schedules.¹⁰ We also acknowledge that our calculation for the percentage of 18 19 opioid dose reduction is based on self-report of opioid consumption, which is prone to bias. 20 This method of assessment reflects the reality of clinical care delivered in the current study 21 setting (Australia), where patients' adherence to opioid prescribing and tapering advice is not 22 enforced or closely supervised but relies on patient self-report. To minimise potential bias, 23 we will collect prescribed/dispensed opioid medication data from electronic monitoring 24 systems as a second source of information. Also, to minimise the risk of social desirability 25 effects on opioid dose reporting, participants are reminded that their assessments, including

23

1	medication reporting, will be confidential and not reported back to their clinician. We also
2	acknowledge the study limitation regarding the control condition. Designing a sham or
3	placebo digital health is challenging for this study. Therefore, we used an active control
4	condition (an educational video) and the limited disclosure method to achieve masking.
5	However, the educational video is likely to provide benefits to the participants as it has been
6	shown to improve proximal outcomes including perceived tapering effectiveness and tapering
7	self-efficacy, ²¹ and can promote health behaviour change. ²² This may lead to an
8	underestimation of the actual effect size of the digital support.
9	

10 Acknowledgements

11 We acknowledge the Ernest Heine Family Foundation for supporting this study with a

- 12 philanthropic gift to the University of Sydney. MLF holds an NHMRC Investigator Grant.
- 13

14 **References**

15	1. Blyth FM, Huckel Schneider C. Global burden of pain and global pain policy-creating a purposeful
16	body of evidence. <i>Pain</i> 2018;159 Suppl 1:S43-S48. doi: 10.1097/j.pain.000000000001311
17	[published Online First: 2018/08/17]
18	2. Black-Tiong S, Gonzalez-Chica D, Stocks N. Trends in long-term opioid prescriptions for
19	musculoskeletal conditions in Australian general practice: a national longitudinal study using
20	MedicineInsight, 2012-2018. <i>BMJ Open</i> 2021;11(4):e045418. doi: 10.1136/bmjopen-2020-
21	045418 [published Online First: 2021/04/09]
22	3. Dowell D, Ragan KR, Jones CM, et al. CDC Clinical Practice Guideline for Prescribing Opioids for
23	Pain - United States, 2022. MMWR Recomm Rep 2022;71(3):1-95. doi:
24	10.15585/mmwr.rr7103a1 [published Online First: 2022/11/04]
25	4. Bohnert ASB, Guy GP, Jr., Losby JL. Opioid Prescribing in the United States Before and After the
26	Centers for Disease Control and Prevention's 2016 Opioid Guideline. Ann Intern Med
27	2018;169(6):367-75. doi: 10.7326/M18-1243 [published Online First: 2018/09/01]
28	5. Frank JW, Lovejoy TI, Becker WC, et al. Patient Outcomes in Dose Reduction or Discontinuation of
29	Long-Term Opioid Therapy: A Systematic Review. Ann Intern Med 2017;167(3):181-91. doi:
30	10.7326/M17-0598 [published Online First: 2017/07/18]
31	6. Fishbain DA, Pulikal A. Does Opioid Tapering in Chronic Pain Patients Result in Improved Pain or
32	Same Pain vs Increased Pain at Taper Completion? A Structured Evidence-Based Systematic
33	Review. Pain Med 2019;20(11):2179-97. doi: 10.1093/pm/pny231 [published Online First:
34	2019/01/01]
35	7. McNeilage AG, Avery NS, Holliday S, et al. A qualitative trajectory analysis of patients' experiences
36	tapering opioids for chronic pain. <i>Pain</i> 2022;163(2):e246-e60. doi:
37	10.1097/j.pain.0000000000002336 [published Online First: 2021/05/15]

1 2	8. Henry SG, Paterniti DA, Feng B, et al. Patients' Experience With Opioid Tapering: A Conceptual Model With Recommendations for Clinicians. <i>J Pain</i> 2019;20(2):181-91. doi:
3	10.1016/j.jpain.2018.09.001 [published Online First: 2018/09/24]
4	9. Agnoli A, Xing G, Tancredi DJ, et al. Association of Dose Tapering With Overdose or Mental Health
5	Crisis Among Patients Prescribed Long-term Opioids. JAMA 2021;326(5):411-19. doi:
6	10.1001/jama.2021.11013 [published Online First: 2021/08/04]
7	10. Darnall BD, Ziadni MS, Stieg RL, et al. Patient-Centered Prescription Opioid Tapering in
8	Community Outpatients With Chronic Pain. JAMA Intern Med 2018;178(5):707-08. doi:
9	10.1001/jamainternmed.2017.8709 [published Online First: 2018/02/21]
10	11. Nicholas MK, Asghari A, Sharpe L, et al. Reducing the use of opioids by patients with chronic pain:
11	an effectiveness study with long-term follow-up. <i>Pain</i> 2020;161(3):509-19. doi:
12	10.1097/j.pain.0000000000001763 [published Online First: 2019/11/26]
13	12. Frank JW, Levy C, Matlock DD, et al. Patients' Perspectives on Tapering of Chronic Opioid
14	Therapy: A Qualitative Study. <i>Pain Med</i> 2016;17(10):1838-47. doi: 10.1093/pm/pnw078
15	[published Online First: 2016/05/22]
16	13. Kennedy LC, Binswanger IA, Mueller SR, et al. "Those Conversations in My Experience Don't Go
17	Well": A Qualitative Study of Primary Care Provider Experiences Tapering Long-term Opioid
18	Medications. <i>Pain Med</i> 2018;19(11):2201-11. doi: 10.1093/pm/pnx276 [published Online
19	First: 2017/11/11]
20	14. Fiordelli M, Diviani N, Schulz PJ. Mapping mHealth research: a decade of evolution. J Med
21	Internet Res 2013;15(5):e95. doi: 10.2196/jmir.2430 [published Online First: 2013/05/24]
22	15. Marcolino MS, Oliveira JAQ, D'Agostino M, et al. The Impact of mHealth Interventions:
23	Systematic Review of Systematic Reviews. JMIR Mhealth Uhealth 2018;6(1):e23. doi:
24	10.2196/mhealth.8873 [published Online First: 2018/01/19]
25	16. Haskins BL, Lesperance D, Gibbons P, et al. A systematic review of smartphone applications for
26	smoking cessation. <i>Transl Behav Med</i> 2017;7(2):292-99. doi: 10.1007/s13142-017-0492-2
27	[published Online First: 2017/05/21]
28	17. Rinaldi G, Hijazi A, Haghparast-Bidgoli H. Cost and cost-effectiveness of mHealth interventions
29	for the prevention and control of type 2 diabetes mellitus: A systematic review. <i>Diabetes Res</i>
30 31	<i>Clin Pract</i> 2020;162:108084. doi: 10.1016/j.diabres.2020.108084 [published Online First: 2020/02/18]
32	18. Slattery BW, Haugh S, O'Connor L, et al. An Evaluation of the Effectiveness of the Modalities
33	Used to Deliver Electronic Health Interventions for Chronic Pain: Systematic Review With
34	Network Meta-Analysis. J Med Internet Res 2019;21(7):e11086. doi: 10.2196/11086
35	[published Online First: 2019/07/19]
36	19. Ashton-James CE, Glare P, Darnall BD. Out of office hours: scalable, on-demand, digital support
37	for patients tapering prescription opioids. <i>Pain</i> 2020;161(10):2252-54. doi:
38	10.1097/j.pain.0000000000001947 [published Online First: 2020/06/06]
39	20. Magee MR, McNeilage AG, Avery N, et al. mHealth Interventions to Support Prescription Opioid
40	Tapering in Patients With Chronic Pain: Qualitative Study of Patients' Perspectives. JMIR
41	Form Res 2021;5(5):e25969. doi: 10.2196/25969 [published Online First: 2021/05/19]
42	21. Feng B, Malloch YZ, Kravitz RL, et al. Assessing the effectiveness of a narrative-based patient
43	education video for promoting opioid tapering. Patient Educ Couns 2021;104(2):329-36. doi:
44	10.1016/j.pec.2020.08.019 [published Online First: 2020/09/10]
45	22. Henry SG, Feng B, Verba S, et al. The story vs the storyteller: Factors associated with the
46	effectiveness of brief video-recorded patient stories for promoting opioid tapering. Health
47	Expect 2021;24(3):991-99. doi: 10.1111/hex.13243 [published Online First: 2021/04/10]
48	23. Darnall BD, Ziadni MS, Krishnamurthy P, et al. "My Surgical Success": Effect of a Digital Behavioral
49	Pain Medicine Intervention on Time to Opioid Cessation After Breast Cancer Surgery-A Pilot
50	Randomized Controlled Clinical Trial. <i>Pain Med</i> 2019;20(11):2228-37. doi:
51	10.1093/pm/pnz094 [published Online First: 2019/05/16]

1 2 3	24. Magee MR, Gholamrezaei A, McNeilage AG, et al. A Digital Video and Text Messaging Intervention to Support People With Chronic Pain During Opioid Tapering: Content Development Using Co-design. <i>JMIR Form Res</i> 2022;6(11):e40507. doi: 10.2196/40507
4	[published Online First: 2022/11/11]
5	25. Magee M, Gholamrezaei A, McNeilage AG, et al. Evaluating acceptability and feasibility of a
6	mobile health intervention to improve self-efficacy in prescription opioid tapering in patients
7	with chronic pain: protocol for a pilot randomised, single-blind, controlled trial. BMJ Open
8	2022;12(4):e057174. doi: 10.1136/bmjopen-2021-057174 [published Online First:
9 10	2022/04/28] 26. Cholamazzazi A. Mazzaz RM. McNailazz AC. at al. Assentability and fassibility of a mabile boolth
10	26. Gholamrezaei A, Magee RM, McNeilage AG, et al. Acceptability and feasibility of a mobile health
11 12	intervention to support patients with chronic pain during opioid tapering: a pilot randomised controlled trial. Presented at: Digital Health Week. Sydney, Australia, 2023 Feb 7-9.
12 13	27. Janevic MR, Mathur VA, Booker SQ, et al. Making Pain Research More Inclusive: Why and How. J
15 14	Pain 2022;23(5):707-28. doi: 10.1016/j.jpain.2021.10.004 [published Online First:
14 15	2021/10/23]
16	28. Hogg MN, Kavanagh A, Farrell MJ, et al. Waiting in Pain II: An Updated Review of the Provision of
10	Persistent Pain Services in Australia. <i>Pain Med</i> 2021;22(6):1367-75. doi:
18	10.1093/pm/pnaa374 [published Online First: 2020/10/28]
19	29. Krebs EE, Lorenz KA, Bair MJ, et al. Development and initial validation of the PEG, a three-item
20	scale assessing pain intensity and interference. J Gen Intern Med 2009;24(6):733-8. doi:
21	10.1007/s11606-009-0981-1 [published Online First: 2009/05/07]
22	30. National Statement on Ethical Conduct in Human Research 2007 (Updated 2018). The National
23	Health and Medical Research Council, the Australian Research Council and Universities
24	Australia. Commonwealth of Australia, Canberra. 2018.
25	31. Treede RD, Rief W, Barke A, et al. A classification of chronic pain for ICD-11. <i>Pain</i>
26	2015;156(6):1003-07. doi: 10.1097/j.pain.0000000000000160 [published Online First:
27	2015/04/07]
28	32. Australian Goverment - Department of Health and Aged Care. National Real Time Prescription
29	Monitoring (RTPM) [Available from: <u>https://www.health.gov.au/our-work/national-real-</u>
30	time-prescription-monitoring-rtpm.
31	33. Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials:
32	IMMPACT recommendations. <i>Pain</i> 2003;106(3):337-45. doi: 10.1016/j.pain.2003.08.001
33	[published Online First: 2003/12/09]
34	34. Gewandter JS, Smith SM, Dworkin RH, et al. Research approaches for evaluating opioid sparing in
35	clinical trials of acute and chronic pain treatments: Initiative on Methods, Measurement, and
36	Pain Assessment in Clinical Trials recommendations. <i>Pain</i> 2021;162(11):2669-81. doi:
37	10.1097/j.pain.0000000000002283 [published Online First: 2021/04/18]
38	35. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med
39	Singap 1994;23(2):129-38. [published Online First: 1994/03/01]
40	36. Walton DM, Beattie T, Putos J, et al. A Rasch analysis of the Brief Pain Inventory Interference
41	subscale reveals three dimensions and an age bias. <i>J Clin Epidemiol</i> 2016;74:218-26. doi:
42	10.1016/j.jclinepi.2015.10.022 [published Online First: 2016/01/16]
43	37. Chen CX, Kroenke K, Stump T, et al. Comparative Responsiveness of the PROMIS Pain
44	Interference Short Forms With Legacy Pain Measures: Results From Three Randomized
45 46	Clinical Trials. <i>J Pain</i> 2019;20(6):664-75. doi: 10.1016/j.jpain.2018.11.010 [published Online
46 47	First: 2018/12/12]
47 48	38. Krebs EE, Bair MJ, Damush TM, et al. Comparative responsiveness of pain outcome measures among primary care patients with musculoskeletal pain. <i>Med Care</i> 2010;48(11):1007-14. doi:
48 49	10.1097/MLR.0b013e3181eaf835 [published Online First: 2010/09/22]

1	39. Kroenke K, Spitzer RL, Williams JB, et al. Anxiety disorders in primary care: prevalence,	
2	impairment, comorbidity, and detection. Ann Intern Med 2007;146(5):317-25. doi:	
3	10.7326/0003-4819-146-5-200703060-00004 [published Online First: 2007/03/07]	
4	40. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item	
5	depression screener. <i>Med Care</i> 2003;41(11):1284-92. doi:	
6	10.1097/01.MLR.0000093487.78664.3C [published Online First: 2003/10/30]	
7	41. Scott W, McCracken LM. Patients' impression of change following treatment for chronic pain:	
8	global, specific, a single dimension, or many? <i>J Pain</i> 2015;16(6):518-26. doi:	
9	10.1016/j.jpain.2015.02.007 [published Online First: 2015/03/10]	
10	42. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials:	
11	IMMPACT recommendations. <i>Pain</i> 2005;113(1-2):9-19. doi: 10.1016/j.pain.2004.09.012	
12	[published Online First: 2004/12/29]	
13	43. Australian and New Zealand College of Anaesthetists. Opioid Dose Equivalence Calculation Table	
14	2021 [Available from: https://www.anzca.edu.au/getattachment/6892fb13-47fc-446b-a7a2-	
15	11cdfe1c9902/PS01(PM)-(Appendix)-Opioid-Dose-Equivalence-Calculation-Table accessed	
16	14 Dec 2021.	
17	44. Nicholas MK. The pain self-efficacy questionnaire: Taking pain into account. Eur J Pain	
18	2007;11(2):153-63. doi: 10.1016/j.ejpain.2005.12.008 [published Online First: 2006/02/01]	
19	45. Bandura A. Guide for Constructing Self-Efficacy Scales. In: Pajares F, Urdan TC, eds. Self-Efficacy	
20	Beliefs of Adolescents. Greenwich, Conn: Information Age Publishing 2006:307-37.	
21	46. Amtmann D, Bamer AM, Liljenquist KS, et al. The Concerns About Pain (CAP) Scale: A Patient-	
22	Reported Outcome Measure of Pain Catastrophizing. J Pain 2020;21(11-12):1198-211. doi:	
23	10.1016/j.jpain.2020.03.004 [published Online First: 2020/06/17]	
24	47. Fritsch CG, Ferreira PH, Prior JL, et al. TEXT4myBACK - The Development Process of a Self-	
25	Management Intervention Delivered Via Text Message for Low Back Pain. Arch Rehabil Res	
26	Clin Transl 2021;3(2):100128. doi: 10.1016/j.arrct.2021.100128 [published Online First:	
27	2021/06/29]	
28	48. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)a metadata-	
29	driven methodology and workflow process for providing translational research informatics	
30	support. <i>J Biomed Inform</i> 2009;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010 [published	
31	Online First: 2008/10/22]	
32	49. Rozental A, Kottorp A, Forsstrom D, et al. The Negative Effects Questionnaire: psychometric	
33	properties of an instrument for assessing negative effects in psychological treatments. <i>Behav</i>	,
34	<i>Cogn Psychother</i> 2019;47(5):559-72. doi: 10.1017/S1352465819000018 [published Online	
35	First: 2019/03/16]	
36	50. Kasper J, Heesen C, Kopke S, et al. Patients' and observers' perceptions of involvement differ.	
37	Validation study on inter-relating measures for shared decision making. PLoS One	
38	2011;6(10):e26255. doi: 10.1371/journal.pone.0026255 [published Online First: 2011/11/02]	
39	51. Kocalevent RD, Berg L, Beutel ME, et al. Social support in the general population: standardization	
40	of the Oslo social support scale (OSSS-3). <i>BMC Psychol</i> 2018;6(1):31. doi: 10.1186/s40359-	
41	018-0249-9 [published Online First: 2018/07/19]	
42	52. Mataix-Cols D, Andersson E. Ten Practical Recommendations for Improving Blinding Integrity and	
43	Reporting in Psychotherapy Trials. <i>JAMA Psychiatry</i> 2021;78(9):943-44. doi:	
44	10.1001/jamapsychiatry.2021.1419 [published Online First: 2021/06/24]	
45	53. Langenderfer-Magruder L, Wilke DJ. The Use of Text Message Reminders to Increase Completion	
46	of Web-Based Surveys: Results of Two Randomized Control Trials. Journal of Technology in	
47	Human Services 2020;38(1):22-37. doi: 10.1080/15228835.2019.1583154	
48	54. Braun V, Clarke V. To saturate or not to saturate? Questioning data saturation as a useful	
49	concept for thematic analysis and sample-size rationales. Qualitative Research in Sport,	
50	Exercise and Health 2021;13(2):201-16. doi: 10.1080/2159676X.2019.1704846	

1 2 3 4	 Lee H, Cashin AG, Lamb SE, et al. A Guideline for Reporting Mediation Analyses of Randomized Trials and Observational Studies: The AGReMA Statement. JAMA 2021;326(11):1045-56. doi: 10.1001/jama.2021.14075 [published Online First: 2021/09/22] Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the
5 6	Bonferroni vs Holm methods. <i>Am J Public Health</i> 1996;86(5):726-8. doi: 10.2105/ajph.86.5.726 [published Online First: 1996/05/01]
7 8 9	57. Twisk JW, Rijnhart JJ, Hoekstra T, et al. Intention-to-treat analysis when only a baseline value is available. <i>Contemp Clin Trials Commun</i> 2020;20:100684. doi: 10.1016/j.conctc.2020.100684 [published Online First: 2020/12/16]
10 11 12	58. Chakraborty H, Gu H. A Mixed Model Approach for Intent-to-Treat Analysis in Longitudinal Clinical Trials with Missing Values. A Mixed Model Approach for Intent-to-Treat Analysis in Longitudinal Clinical Trials with Missing Values. Research Triangle Park (NC)2009.
13 14 15	59. Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci 2009;4:50. doi: 10.1186/1748-5908-4-50 [published Online First: 2009/08/12]
16	
17	Authors Contributions
18	PG and CEAJ conceptualized the interventions and acquired funding and should be
19	considered joint senior author. All authors contributed to the design of the study protocol. AG
20	drafted the study protocol and manuscript. All authors critically reviewed and edited the
21	manuscript and approved its final version.
22	
23	Funding
24	This research was supported by a philanthropic gift to The University of Sydney from the
25	Ernest Heine Family Foundation.
26	
27	Competing interests
28	None declared.

1 Figure legends:

2 Figure 1: Study Flow Diagram

3

- 4 Supplementary Materials
- 5 Appendix 1 The SPIRIT checklist.
- 6 Appendix 2 Study Advertisement Materials.
- 7 Appendix 3 Participant Information Statement and Consent Form.
- 8 Appendix 4 Screening form.
- 9 Appendix 5 Text messages and Video script.
- 10 Appendix 6 Instruction For Digital Health Support.




Figure 1: Study Flow Diagram